Opinion|Videos|April 1, 2024
Localized Therapy in Early- and Intermediate-Stage HCC
Medical oncologists outline localized therapy options for patients with early- and intermediate-stage hepatocellular carcinoma.
Advertisement
Advertisement
Related to this article
Zachary L. Bercu, MD, RPVI, FSIR, discusses the Liberty robotic system’s applications in liver and kidney cancer as well as the feasibility of remote procedures.
Zachary L. Bercu, MD, RPVI, FSIR, explains how the Liberty endovascular robotic system works from the operator’s perspective and what went into becoming its first adopting site.
Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.
Chih-Yi “Andy” Liao, MD, discusses early clinical data for KRAS G12C and G12D inhibitors in cholangiocarcinoma, noting that trials are just getting started.
Chih-Yi “Andy” Liao, MD, discusses how oncologists are sequencing pemigatinib, futibatinib, and lirafugratinib and how their tolerability differs.
Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
How Emory Became the First Adopter of the Liberty Endovascular Robotic System
3
Building out a Radiopharmaceuticals Program in Oncology Care
4
Rinatabart Sesutecan Elicits Responses in PROC Regardless of FRα Expression
5